Exerpts from the publication

Methods: Six randomized, double-blind, controlled clinical trials at five study sites were conducted from April 2004 to February 2017. Active doses of MDMA (75-125 mg, n = 72) or placebo/control doses (0-40 mg, n = 31) were administered to individuals with PTSD during manualized psychotherapy sessions in two or three 8-h sessions spaced a month apart. Three non-drug 90-min therapy sessions preceded the first MDMA exposure, and three to four followed each experimental session.

Results: After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups – 22.0 (5.17), P < 0.001]. The between-group Cohen's d effect size was 0.8, indicating a large treatment effect. After two experimental sessions, more participants in the active group (54.2%) did not meet CAPS-IV PTSD diagnostic criteria than the control group (22.6%). Depression symptom improvement on the BDI-II was greatest for the active group compared to the control group, although only trended towards significant group differences [MMRM, estimated mean difference (SE) between groups - 6.0 (3.03), P = 0.053]. All doses of MDMA were well tolerated, with some expected reactions occurring at greater frequency for the active MDMA group during experimental sessions and the 7 days following. Conclusions: MDMA-assisted psychotherapy was efficacious and well tolerated in a large sample of adults with PTSD. These studies supported expansion into phase 3 trials and led to FDA granting Breakthrough Therapy designation for this promising treatment.

Read more

Trial of Psilocybin versus Escitalopram for Depression

Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt
April 2021

Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review

Jason Ng, Joshua D Rosenblat, Leanna M W Lui, Kayla M Teopiz, Yena Lee, Orly Lipsitz, Rodrigo B Mansur, Nelson B Rodrigues, Flora Nasri, Hartej Gill, Danielle S Cha, Mehala Subramaniapillai, Roger C Ho , Bing Cao, Roger S McIntyre
October 2021

Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial

Yoav Domany, Richard C Shelton, Cheryl B McCullumsmith
October 2019

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission

Danilo De Gregorio, Jelena Popic, Justine P. Enns, Antonio Inserra, Agnieszka Skalecka, Athanasios Markopoulos, Luca Posa, Martha Lopez-Canul, He Qianzi, Christopher K. Lafferty, Jonathan P. Britt, Stefano Comai, Argel Aguilar-Valles, Nahum Sonenberg, and Gabriella Gobbi
February 2021